Research on the PARP inhibitor talazoparib (Talzenna) for early-stage breast cancer is promising

https://www.facingourrisk.org/XRAY/PARP-inhibitor-for-early-breast-cancer-is-promising

Full article: https://doi.org/10.1200/JCO.19.01304

The PARP inhibitor talazoparib (Talzenna) has been useful for treatment of advanced or metastatic breast cancer for patients with BRCA mutations. A preliminary study showed that the majority of patients who took talazoparib alone before surgery for early-stage breast cancer had effective treatment and manageable side effects. Expanded clinical trials are in progress to verify this result. (10/4/19)

Questions To Ask Your Health Care Provider

What type of treatment is best for me prior to my breast cancer surgery?
Am I eligible for any clinical trials of PARP inhibitors for early-stage breast cancer?
I have metastatic breast cancer; what are the benefits and risks of PARP inhibitor treatment for me?

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.